It has been shown to safely and completely reverse its anticoagulant effects.20 At this point, Andexanet-alpha has undergone in vitro trials and is in phase three of in vivo trials as a universal factor Xa antidote
In the GLP-1 consumer world, snack foods appear to be falling out of favor with some with the Cornell research paper showing an 11% decline in savory snacks in GLP-1 households
[DOI] [PMC free article] [PubMed] [Google Scholar] 39.Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, et al
Min L, Vaidya A, Becker C
In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication